 <h1>Onglyza Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>saxagliptin</i></p><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li>
<li>FAQ</li></ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about saxagliptin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Onglyza.</p><h2>In Summary</h2><p><b>Common side effects of Onglyza include:</b> hypoglycemia.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to saxagliptin: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, saxagliptin (the active ingredient contained in Onglyza) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking saxagliptin:</p><p>
<i>More common</i>
</p><ul>
<li>Anxiety</li>
<li>bladder pain</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>bloody or cloudy urine</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>chills</li>
<li>cold sweats</li>
<li>confusion</li>
<li>cool, pale skin</li>
<li>cough</li>
<li>depression</li>
<li>difficult, burning, or painful urination</li>
<li>difficulty with breathing</li>
<li>dizziness</li>
<li>ear congestion</li>
<li>fast heartbeat</li>
<li>fever</li>
<li>frequent urge to urinate</li>
<li>headache</li>
<li>increased hunger</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nasal congestion</li>
<li>nausea</li>
<li>nightmares</li>
<li>rapid weight gain</li>
<li>runny nose</li>
<li>seizures</li>
<li>shakiness</li>
<li>slurred speech</li>
<li>sneezing</li>
<li>sore throat</li>
<li>tingling of the hands or feet</li>
<li>unusual tiredness or weakness</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Chest pain</li>
<li>constipation</li>
<li>darkened urine</li>
<li>decreased urine output</li>
<li>difficulty with swallowing</li>
<li>dilated neck veins</li>
<li>extreme fatigue</li>
<li>flaking or peeling of the skin</li>
<li>hives or skin rash</li>
<li>indigestion</li>
<li>irregular breathing</li>
<li>irregular heartbeat</li>
<li>large, hard skin blisters</li>
<li>large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs</li>
<li>loss of appetite</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue</li>
<li>severe joint pain</li>
<li>swelling of face, fingers, feet, or lower leg</li>
<li>tightness in the chest</li>
<li>troubled breathing</li>
<li>vomiting</li>
<li>weight gain</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of saxagliptin may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>Less common</i>
</p><ul>
<li>Diarrhea</li>
<li>pain or tenderness around the eyes and cheekbones</li>
<li>redness of the skin</li>
<li>weakness</li>
<li>welts</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to saxagliptin: oral tablet</i></p><h3>General</h3><p>Commonly reported adverse reactions include respiratory tract infection, urinary tract infection, and headache.  Peripheral edema was more commonly reported in patients treated with the combination saxagliptin (the active ingredient contained in Onglyza) and thiazolidinedione.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia</p>
<p><b>Uncommon</b> (0.1% to 1%): Dyslipidemia, hypertriglyceridemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, peripheral edema</p>
<p><b>Frequency not reported</b>: Heart failure<sup>[Ref]</sup></p><p>Hospitalization for heart failure occurred more frequently in patients receiving this drug compared with placebo in a cardiovascular outcomes trial that enrolled patients with established, or multiple risk factors for atherosclerotic cardiovascular disease (3.5% vs 2.8%).  Additionally, in the time to first event analysis, the risk of hospitalization was higher compared to placebo (Hazard Ratio 1.27; 95% confidence interval 1.07 to 1.51).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p>
<p><b>Uncommon</b> (0.1% to 1%): Dermatitis, pruritus, urticaria</p>
<p><b>Rare</b> (less than 0.1%): Angioedema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In a cardiovascular outcomes trial that enrolled patients with established, or multiple risk factors for atherosclerotic cardiovascular disease, acute pancreatitis was confirmed in 0.2% (17 of 8240) patients receiving this drug compared with 0.1% (9 of 8173) of the placebo-treated patients.  Preexisting risk factor were identified in 88% and 100% of the drug treated patients and placebo patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Gastroenteritis, vomiting, nausea, dyspepsia, gastritis, flatulence</p>
<p><b>Uncommon</b> (0.1% to 1%): Pancreatitis</p>
<p><b>Frequency not reported</b>: Abdominal pain</p>
<p><b>Postmarketing reports</b>: Acute pancreatitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p>
<p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction (with metformin)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased, anemia, decreased in absolute lymphocyte count (dose related)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, back pain</p>
<p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, sinusitis, nasopharyngitis, bronchitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p>
<p><b>Rare</b> (less than 0.1%): Anaphylactic reactions including anaphylactic shock</p>
<p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p></div>
<h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2>
<ul>
<li>What are the ingredient drugs contained in Qternmet XR?</li>
</ul>
<div class="more-resources" id="moreResources">
<h2>More about Onglyza (saxagliptin)</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>15 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Onglyza &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to saxagliptin: oral tablet</i></p><h3>General</h3><p>Commonly reported adverse reactions include respiratory tract infection, urinary tract infection, and headache.  Peripheral edema was more commonly reported in patients treated with the combination saxagliptin (the active ingredient contained in Onglyza) and thiazolidinedione.<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Hypoglycemia</p><p><b>Uncommon</b> (0.1% to 1%): Dyslipidemia, hypertriglyceridemia<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Hypertension, peripheral edema</p><p><b>Frequency not reported</b>: Heart failure<sup>[Ref]</sup></p><p>Hospitalization for heart failure occurred more frequently in patients receiving this drug compared with placebo in a cardiovascular outcomes trial that enrolled patients with established, or multiple risk factors for atherosclerotic cardiovascular disease (3.5% vs 2.8%).  Additionally, in the time to first event analysis, the risk of hospitalization was higher compared to placebo (Hazard Ratio 1.27; 95% confidence interval 1.07 to 1.51).<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash</p><p><b>Uncommon</b> (0.1% to 1%): Dermatitis, pruritus, urticaria</p><p><b>Rare</b> (less than 0.1%): Angioedema<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p>In a cardiovascular outcomes trial that enrolled patients with established, or multiple risk factors for atherosclerotic cardiovascular disease, acute pancreatitis was confirmed in 0.2% (17 of 8240) patients receiving this drug compared with 0.1% (9 of 8173) of the placebo-treated patients.  Preexisting risk factor were identified in 88% and 100% of the drug treated patients and placebo patients, respectively.<sup>[Ref]</sup></p><p><b>Common</b> (1% to 10%): Gastroenteritis, vomiting, nausea, dyspepsia, gastritis, flatulence</p><p><b>Uncommon</b> (0.1% to 1%): Pancreatitis</p><p><b>Frequency not reported</b>: Abdominal pain</p><p><b>Postmarketing reports</b>: Acute pancreatitis<sup>[Ref]</sup></p><h3>Genitourinary</h3><p><b>Common</b> (1% to 10%): Urinary tract infection</p><p><b>Uncommon</b> (0.1% to 1%): Erectile dysfunction (with metformin)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Common</b> (1% to 10%): Blood creatine phosphokinase increased, anemia, decreased in absolute lymphocyte count (dose related)<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Common</b> (1% to 10%): Myalgia, back pain</p><p><b>Uncommon</b> (0.1% to 1%): Arthralgia<sup>[Ref]</sup></p><p>Between October 2006 and December 2013, thirty-three cases of severe arthralgia have been reported to the FDA Adverse Event Reporting System Database.  Each case involved the use of 1 or more dipeptidyl peptidase-4 (DPP-4) inhibitor.  In all cases, substantial reduction in prior activity level was reported, 10 patients were hospitalized due to disabling joint pain.  In 22 cases, symptoms appeared within 1 month of starting therapy, in 23 cases symptoms resolved less than 1 month after discontinuation.  A positive rechallenge was reported in 8 cases, with 6 cases involving use of a different DPP-4 inhibitor.  Sitagliptin had the greatest number of cases reported (n=28) followed by saxagliptin (n=5), linagliptin (n=2), alogliptin (n=1), and vildagliptin (n=2).<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Common</b> (1% to 10%): Headache, dizziness<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Fatigue<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Common</b> (1% to 10%): Anxiety, depression<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Common</b> (1% to 10%): Upper respiratory tract infection, sinusitis, nasopharyngitis, bronchitis<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Uncommon</b> (0.1% to 1%): Hypersensitivity reactions</p><p><b>Rare</b> (less than 0.1%): Anaphylactic reactions including anaphylactic shock</p><p><b>Postmarketing reports</b>: Anaphylaxis, angioedema, rash, urticaria<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "Australian Product Information." O 0</p><p id="ref_2">2. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_3">3. "Product Information. Onglyza (saxagliptin)." Bristol-Myers Squibb, Princeton, NJ. </p><p id="ref_4">4. US Food and Drug Administration "FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. Available from: URL: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM460038.pdf."   ([2015, Aug 28]):</p><h2 class="ddc-anchor-offset" id="faq">Frequently asked questions</h2><ul>
<li>What are the ingredient drugs contained in Qternmet XR?</li>
</ul><h2>More about Onglyza (saxagliptin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Images</li>
<li>Drug Interactions</li>
<li>Pricing &amp; Coupons</li>
<li>En Espa√±ol</li>
<li>15 Reviews</li>
<li>Drug class: dipeptidyl peptidase 4 inhibitors</li>
<li>FDA Alerts (3)</li>
<li>FDA Approval History</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Onglyza &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Diabetes, Type 2</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>